Navigation Links
Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
Date:12/4/2008

LAUSANNE, Switzerland, December 4 /PRNewswire/ -- AC Immune SA, a leader in Alzheimer's disease drug development, announced today that the World Economic Forum has elected AC Immune as Technology Pioneer 2009 for its accomplishments as an innovation leader and for its breakthrough technologies that can have a deep impact on business and society.

Furthermore, AC Immune released that it has reached significant clinical milestones in the development of innovative therapies against Alzheimer's disease. The regulatory authorities have approved the Phase II clinical trial application of the small molecule ACI-91 for the treatment of mild to moderate Alzheimer's disease.

Thirdly, AC Immune disclosed that Genentech Inc., which develops the anti-Abeta antibody under an exclusive license agreement with AC Immune, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the clinical development program in mild to moderate Alzheimer's disease. Enrollment of the first patient in the Phase I clinical study during the third quarter of 2008 triggered a milestone payment to AC Immune of an undisclosed amount.

About AC Immune SA

AC Immune SA is leader in Alzheimer's disease drug development with their corporate headquarters in Ecublens/Lausanne, Switzerland. AC Immune combines its proprietary immunology (SupraAntigen(TM)) and chemistry (Morphomers(TM)) platform technologies to generate conformation-specific Alzheimer's therapies. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer's Disease along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody for passive immunization is partnered with Genentech and entered clinical Phase I trial in 2008. Two proprietary products, ACI-24 (vaccine) and ACI-91 (small molecule) are entering clinical trials in 2008/2009 and are backed by a rich portfolio of compounds at preclinical stage. Therapeutic molecules are leveraged for Alzheimer's disease diagnostic and other CNS and non-CNS diseases. Since its foundation in 2003, the company has raised CHF24 million in two financing rounds. At the end of 2006, the company closed a more than US$300 million out-licensing agreement with Genentech.

    For the full press release, please go tohttp://www.acimmune.com

    Contact:
    Prof. Andrea Pfeifer
    Chief Executive Officer
    Phone: +41-21-693-91-23
    E-Mail: andrea.pfeifer@acimmune.com
    Internet:http://www.acimmune.com

    Eva Schier
    Corporate Communications Manager
    Phone: +41-21-693-91-34
    E-Mail: eva.schier@acimmune.com
    Internet:http://www.acimmune.com



'/>"/>
SOURCE AC Immune SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October ... on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker ... is free and open to the public, but registration is required. , WHAT: ...
(Date:10/5/2017)... ... ... Understanding the microbiome, the millions of bacteria that live in our guts, ... Future, the newest exhibit on display at the University City Science Center’s Esther Klein ... lens of the gut microbiome. , Gut Love opens October 12, 2017, and ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
Breaking Biology News(10 mins):